The present invention is related to a composition comprising a phosphodiesterase inhibitor, such as anagrelide or a salt thereof, for use in the treatment of a solid tumor, such as gastrointestinal stromal tumor (GIST) or a liposarcoma, which express phosphodiesterase 3 enzymes, in a human patient.